ENA-001 restores ventilation as a peripherally directed (carotid body) BK-channel antagonist with a mechanism independent of MOR, and is "agnostic" to the drug cause of respiratory depression. Here, KCNMA1 is linked to Respiratory insufficiency due to muscle weakness.